Effects of sputum oscillations and rhDNase in vitro: A combined approach to treat cystic fibrosis lung disease

Pediatric Pulmonology

Volumn 26, Issue 4, 1998, Pages 250-255

  Dasgupta, Bonnie ^a   Brown, Neil E ^a   King, Malcolm ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cystic fibrosis; RhDNase; Sputum clearance; Sputum oscillations; Sputum viscoelasticity

Indexed keywords

DEOXYRIBONUCLEASE; DORNASE ALFA;

AIRWAY DYNAMICS; ARTICLE; CYSTIC FIBROSIS; DEVICE; FLOW RATE; HUMAN; IN VITRO STUDY; LUNG CLEARANCE; MOLECULAR WEIGHT; MUCOLYSIS; OSCILLATION; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; VISCOELASTICITY;

ADULT; COMBINED MODALITY THERAPY; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; ELASTICITY; HUMANS; RECOMBINANT PROTEINS; RESPIRATORY THERAPY; SPUTUM; VISCOSITY;

EID: 0031782330     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199810)26:4<250::AID-PPUL3>3.0.CO;2-X     Document Type: Article

References (31)

1. Boat TF, Welsh MJ, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, 6th ed, vol. 2. New York: McGraw-Hill, 1989; 2649-2680.
2. Dasgupta B, Tomkiewicz RP, Boyd WA, Brown NE, King M. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro. Pediatr Pulmonol. 1995; 20:78-82.
3. Konstan MW, Stern RC, Doershuk CF. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr. 1994; 124:689-693.
4. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA. 1990; 87:9188-9192.
5. Matthews LW, Spector S, Lemm J, Potter JL. Studies on pulmonary secretions. 1. The over-all chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis and laryngectomy. Am Rev Respir Dis. 1963; 88:199-204.
6. Picot R, Das I, Reid L. Pus, deoxyribonucleic acid and sputum viscosity. Thorax. 1978; 33:235-242.
7. Lethem MI, James SL, Marriott C, Burke JF. The origin of DNA associated with mucous glycoproteins in cystic fibrosis sputum. Eur Respir J. 1990; 3:19-23.
8. Rubin BK, Ramirez O, Shak S, Toy KJ, Sinicropi D. DNA concentration of CF sputum correlates with hydration and spinnability but not with viscoelasticity. Pediatr Pulmonol. 1994; 10S:241 [Abstract].
9. Zahm JM, Girod de Bentzmann S, Deneuville E, Perror-Minnot C, Depret E, Pennaforte F, Roussey M, Puchelle E. Dose-dependent in vitro effect of recombinant human DNase on the transport properties of cystic fibrosis respiratory mucus. Eur Respir J. 1995; 8:381-386.
10. Shah PL, Ingham S, Marriott C, Scott SF, Hodson ME. The in vitro effects of two novel drugs on the rheology of cystic fibrosis and bronchiectasis sputum. Eur Respir J. 1994; 7:12s [Abstract].
11. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in cystic fibrosis. N Engl J Med. 1994; 331:637-648.
12. Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs H, Empey D, Geddes D, Hodson M. Efficacy and safety of short-term administration of aerosolized recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet. 1993; 342:199-202.
13. Lindemann H. Zum Stellenwert der Physiotherapie mit dem VRP1-Desitin ("Flutter"). Pneumologie. 1992; 46:626-630.
14. Nakamura S, Kawakami M. Effects of the Flutter®, a physiotherapeutic device, on sputum clearance. Jpn J Appl Physiol. 1995; 25S:149-152.
15. App EM, Kieselmann R, Reinhardt D, Lindemann H, Dasgupta B, King M, Brand P. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy - Flutter vs. autogenic drainage. Chest. 1998;114:171-177.
16. Dasgupta B, King M. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase. Pediatr Pulmonol. 1996; 22:161-166.
17. King M, Dasgupta B, Tomkiewicz RP, Brown NE. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with rhDNase. Am J Respir Crit Care Med. 1997; 156:173-177.
18. Dasgupta B, App EM, King M. Effects of the Flutter device and airflow oscillations on spinnability of cystic fibrosis sputum. Am J Respir Crit Care Med. 1996; 153:A69 [Abstract].
19. Dasgupta B, Chen M, King M. Effects of different airflows produced by the flutter device on cohesiveness of cystic fibrosis sputum. Am J Respir Crit Care Med. 1997; 155:A49 [Abstract].
20. King M, Brock G, Lundell C. Clearance of mucus by simulated cough. J Appl Physiol. 1985; 58:1776-1782.
21. King M, Macklem PT. Rheological properties of microliter quantities of normal mucus. J Appl Physiol. 1977; 42:797-802.
22. King M. Magnetic microrheometer. In: Braga PC, Allegra L, eds. Methods in Bronchial Mucology. New York: Raven Press, 1987; 73-83.
23. Zayas JG, Man GWC, King M. Tracheal mucus rheology in patients undergoing diagnostic bronchoscopy: Interrelations with smoking and cancer. Am Rev Respir Dis. 1990; 141:1107-1113.
24. King M. Role of mucus viscoelasticity in cough clearance. Biorheology. 1987; 24:589-597.
25. MacLusky I, McLaughlin FJ, Levison H. Cystic fibrosis. Curr Probl Pediatr. 1985; 15:1-49.
26. Dasgupta B. Tomkiewicz RP, De Sanctis GT, Boyd WA, King M. Rheological properties in cystic fibrosis airway secretions with combined rhDNase and gelsolin treatment. In: Singh M, Saxena VP, eds. Advances in Physiological Fluid Dynamics. New Delhi: Narosa, 1996; 74-78.
27. Soland V, Brock G, King M. Effect of airway wall flexibility on clearance by simulated cough. J Appl Physiol. 1987; 63:707-712.
28. Cegla UH, Retzow A. Physiotherapie mit dem VRP1 bei chronisch obstruktiven Atemwegserkrankungen - Ergebnisse einer multizentrischen Vergleichsstudie. Pneumologie 1993; 47:636-639.
29. Alton E, Caplen N, Geddes D, Williamson R. New treatments for cystic fibrosis [Review]. Br Med Bull. 1992; 48:785-804.
30. Lazarides E, Lindberg U. Actin is the naturally occurring inhibitor of deoxyribonuclease 1. Proc Natl Acad Sci USA. 1974; 71:4742-4746.
31. Hitchcock SE, Carlsson L, Lindberg U. Depolymerization of F-actin by deoxyribonuclease 1. Cell. 1976; 7:531-542.